ArkeaBio's methane vaccine to curb GHG emissions

Last month, leading ag-biotech start-up ArkeaBio announced the close of a US$26.5mn Series A financing round aimed at advancing their methane reducing vaccine R&D

ArkeaBio's vaccine will provide an innovative, cost-effective and scalable solution to reduce the world’s livestock methane emissions, which currently generate the equivalent of 3 bn tonnes of CO2 annually and represent 6% of annual greenhouse gas (GHG) emissions. Results from the company's R&D have garnered substantial attention from investors for the advancement of the inaugural methane-reducing vaccine.

The funds raised in this Series A financing will play a pivotal role in expanding the research, development and deployment of the vaccine, including large-scale field trials and engagement along the supply chain. The company aims to bring this transformative solution to the market through collaborative efforts with industry partners, regulatory authorities, and environmental organisations. 

“We are thankful for the financial support, confidence, and trust of our investors. This funding will accelerate the development of our vaccine-based solution to meet a pressing global problem,” said ArkeaBio CEO, Colin South. “To echo the sentiments of The Grantham Foundation: ‘climate change is the greatest challenge humanity has ever faced. It is the race of our lives.’ This capital raise allows us to continue to create the tools necessary for farmers to achieve globally relevant reductions in livestock methane emissions.”

For more information, visit: www.arkeabio.com